Datroway (Datopotamab Deruxtecan) Projected peak annual sales: USD 5 billion Datopotamab deruxtecan, jointly developed by Daiichi Sankyo and AstraZeneca, is a specifically engineered TROP2-directed DXd ADC used for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and EGFR-mutated non-small cell lung cancer (NSCLC)
Zinc is essential for DNA synthesis, cell proliferation, and tissue repair
Clinical Evidence in Humans The topical evidence base is unusually robust for a research peptide: Facial aging study (71 women, 12 weeks): A GHK-Cu facial cream documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and depth of wrinkles (PMID 26236730)
Louis ED, Lee M, Babij R, Ma K, Corts E, Vonsattel JPG, et al
Dont be blinded by marketing jargon